Search
SF Healthcare Week: Recursion's new CEO Najat Khan shares her vision for the company and for AI in biotech
Najat Khan describes the impact Recursion's work is having, such the surprising PoC of using MEK1/2 inhibition as a target for treating Familial Adenomatous Polyposis (PAP). Plus, she discusses other programs and large-pharma partnerships, and using new tools such as Boltz-2.
Jan 15
AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with...
Jul 23, 2025
SF Healthcare Week: Recursion Co-Founder & CEO Chris Gibson talks the Exscientia merger, Recursion's scale and capabilities, and key targets in development
He discusses the merger that completed towards the end of last year, Recursion's computational and wet lab abilities, cerebral cavernous...
Jan 15, 2025
Recursion's Chris Gibson on the potential utility of machine learning and AI in drug development
Chris Gibson describes the new technologies that are accelerating and refining drug development.
Jan 11, 2024
.png){kind=logo}
